Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 15027319

[Fascinated by pulmonary function].

Masayuki Kambe
View original source ↗Export metadata ↓

Abstract

I would like to tell you about my 35 years of research, starting when I became a medical doctor, titled "Fascinated by Pulmonary Function". For the first 10 years, I studied the automation of pulmonary function tests and developed some automatic pulmonary function test apparatuses such as the spiro-computer, panspiro-computer, automatic respiratory resistant test apparatus and automatic respiratory central function test apparatus. For the next 15 years, I studied the relationships between some important pulmonary diseases and respiratory pulmonary functions. In particular, I studied respiratory efficiency and respiratory center functions. For the most recent 10 years, I have been studying the relationships between non-respiratory pulmonary functions and chronic respiratory diseases. I am studying the relationships between ATP(Adenosine Tri Phosphate) in the blood for the parameters of mitochondria function and pneumoconiosis and other chronic pulmonary diseases. I had very interesting results regarding DNA types of arteriosclerosis in chronic pulmonary emphysema. I thank all my research fellows during these 35 years from the bottom of my heart.

Explore related subjects

Adenosine TriphosphateHistory, 20th CenturyHistory, 21st CenturyHumansJapanPulmonary MedicineRespirationRespiratory CenterRespiratory Function TestsBiographyEnglish AbstractHistorical ArticleJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Masayuki Kambe. 2004. [Fascinated by pulmonary function].. https://pubmed.ncbi.nlm.nih.gov/15027319/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2022

The human mitochondrial genome contains a second light strand promoter.

The human mitochondrial genome must be replicated and expressed in a timely manner to maintain energy metabolism and supply cells with adequate levels of adenosine triphosphate. Central to this process is the idea that replication primers and gene products both arise via transcription from a single light strand promoter (LSP) such that primer formation can influence gene expression, with no consensus as to how this is regulated. Here, we report the discovery of a second light strand promoter (LSP2) in humans, with features characteristic of a bona fide mitochondrial promoter. We propose that the position of LSP2 on the mitochondrial genome allows replication and gene expression to be orchestrated from two distinct sites, which expands our long-held understanding of mitochondrial gene expression in humans.

Adenosine Triphosphate↗
PubMed2021

GCN2 kinase activation by ATP-competitive kinase inhibitors.

Small-molecule kinase inhibitors represent a major group of cancer therapeutics, but tumor responses are often incomplete. To identify pathways that modulate kinase inhibitor response, we conducted a genome-wide knockout (KO) screen in glioblastoma cells treated with the pan-ErbB inhibitor neratinib. Loss of general control nonderepressible 2 (GCN2) kinase rendered cells resistant to neratinib, whereas depletion of the GADD34 phosphatase increased neratinib sensitivity. Loss of GCN2 conferred neratinib resistance by preventing binding and activation of GCN2 by neratinib. Several other Food and Drug Administration (FDA)-approved inhibitors, such erlotinib and sunitinib, also bound and activated GCN2. Our results highlight the utility of genome-wide functional screens to uncover novel mechanisms of drug action and document the role of the integrated stress response (ISR) in modulating the response to inhibitors of oncogenic kinases.

Adenosine Triphosphate↗
PubMed2005

Probing ATP-dependent conformational changes in the multidrug resistance protein 1 (MRP1/ABCC1) in live tumor cells with a novel recombinant single-chain Fv antibody targeted to the extracellular N-terminus.

The multidrug resistance protein 1 (MRP1/ABCC1) is an ATP-driven transporter that mediates the cellular extrusion of various chemotherapeutic agents. We have previously isolated a novel recombinant single-chain Fv antibody (A5scFv), which specifically targets the extracellular N-terminus of the human MRP1 expressed on the surface of live tumor cells. Fusion of A5scFv to Pseudomonas exotoxin revealed an immunotoxin that bound to the immobilized MRP1-derived peptide upon ELISA, but surprisingly failed to recognize MRP1 on the surface of live tumor cells. As these results suggested that the N-terminus of MRP1 has a limited accessibility to the extracellular space, we used the A5scFv antibody to probe for putative conformational changes that might occur in viable tumor cells upon ATP binding. A5scFv recognized viable MRP1-expressing cells with intact ATP pools, whereas ATP depletion resulted in the loss of A5scFv reactivity. Consistently, restoration of cellular ATP levels resulted in resumption of A5scFv binding to MRP1 in live tumor cells. Flow cytometric analysis confirmed that ATP-depleted cells accumulated significantly higher levels of the established substrate calcein AM, whereas after restoration of cellular ATP pools, cells displayed a much lower level of calcein AM accumulation. Moreover, pretreatment of MRP1-expressing cells with the membrane fluidizer benzyl alcohol resulted in a dramatic increase in A5scFv reactivity, suggesting that membrane fluidization results in the exposure of the N-terminus of MRP1 to the extracellular milieu. These results constitute the first extracellular probing of the putative conformational changes that MRP1 adopts in viable tumor cells upon ATP binding. Furthermore, although ATP binding occurs in the cytosolic nucleotide binding domains of MRP1, significant conformational changes are apparently propagated to the N-terminus residing at the extracellular compartment.

Adenosine Triphosphate↗